Search results
Results From The WOW.Com Content Network
Meta-analytic evidence showed that add-on modafinil and armodafinil were more effective than placebo on response to treatment, clinical remission, and reduction in depressive symptoms, with only minor side effects, but the effect sizes are small and the quality of evidence has to be considered low, limiting the clinical relevance of current ...
Modafinil is generally well-tolerated but can have potential risks and side effects. Common adverse effects of modafinil, experienced by less than 10% of users, include headaches, nausea, and reduced appetite. [93] [94] [20] Anxiety, insomnia, dizziness, diarrhea, and rhinitis are also reported in 5% to 10% of users. [20]
Solriamfetol is used to promote wakefulness in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adults. [1] It appears to be more effective in improving excessive daytime sleepiness associated with obstructive sleep apnea than certain other wakefulness-promoting agents including modafinil, armodafinil, and pitolisant.
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.
Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about them.
Note: "Notable" is to mean side-effects that are particularly unique to the antipsychotic drug in question. For example, clozapine is notorious for its ability to cause agranulocytosis. If data on the propensity of a particular drug to cause a particular AE is unavailable an estimation is substituted based on the pharmacologic profile of the drug.
Some reports in a review supported by Novo Nordisk suggested that semaglutide may decrease the risk of kidney disease over the long term. But there were also a few reports of folks taking GLP-1s ...
Many patients will not develop these side effects, although there is still a significant possibility of risks associated with Antipsychotic usage. The percentage of patients affected by side effects like Tardive dyskinesia is significantly high and estimated to be a 20-50% prevalence. [1] [2]